Lecanemab: Amyloid Reduction and Evidence of Downstream Biomarker Modification

神经退行性变 胶质增生 生物标志物 萎缩 医学 病理 淀粉样蛋白(真菌学) 安慰剂 脑脊液 神经颗粒素 老年斑 阿尔茨海默病 内科学 化学 疾病 生物化学 替代医学 蛋白激酶C
作者
Michael C. Irizarry
出处
期刊:Alzheimers & Dementia [Wiley]
卷期号:19 (S15) 被引量:1
标识
DOI:10.1002/alz.080907
摘要

Abstract Background Lecanemab is a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils) which has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in a Phase 3 Study in early AD (Study 301). The objective of this analysis is to report biomarker results from Study 301. Methods Study 301 was a double‐blind, randomized, placebo‐controlled study of 1875 patients with early AD randomized to 10 mg/kg IV lecanemab or placebo for 18 months of treatment. Plasma, CSF, and imaging biomarkers of amyloid, tau, neurodegeneration, and gliosis were assessed. Results Lecanemab met all primary and key secondary clinical endpoints with a high degree of statistical significance. Lecanemab improved markers of amyloid with reduction of brain amyloid by PET in as early as 3 months and improvement in CSF Aß42 and plasma Aß42/40. Biomarkers of tau showed improvement in CSF and plasma p‐tau181, and slowing of tau accumulation relative to placebo in the medial temporal regions by tau PET. For biomarkers of neurodegeneration and gliosis, there was improvement in CSF t‐tau, CSF neurogranin, and plasma GFAP. There were no significant differences in CSF or plasma Nf‐L between lecanemab and placebo. Volumetric MRI results were inconsistent, with reduced hippocampal atrophy on lecanemab, but greater cortical volume loss relative to placebo, possibly “pseudoatrophy” related to amyloid mobilization. Conclusions Lecanemab treatment resulted in significant reduction in amyloid plaques and a slowing of clinical decline. Improvements in biomarkers of amyloid, tau, neurodegeneration, and gliosis provide a biological basis for the treatment effects consistent with disease modification.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SciGPT应助feihua采纳,获得10
刚刚
刚刚
刚刚
dongdong发布了新的文献求助10
1秒前
1秒前
sdl发布了新的文献求助10
1秒前
1秒前
沉静丹寒发布了新的文献求助10
2秒前
泽丶完成签到,获得积分10
2秒前
AI_S发布了新的文献求助10
2秒前
情怀应助周常通采纳,获得10
3秒前
知栀完成签到 ,获得积分10
4秒前
lubo发布了新的文献求助10
4秒前
4秒前
SUN发布了新的文献求助10
4秒前
4秒前
4秒前
大个应助石贵远采纳,获得10
4秒前
九点半上课了完成签到,获得积分10
5秒前
hang完成签到,获得积分10
6秒前
6秒前
8秒前
dwct完成签到,获得积分10
8秒前
8秒前
Mxs发布了新的文献求助10
9秒前
丘比特应助TOMORI酱采纳,获得10
9秒前
任性的冷梅完成签到,获得积分10
9秒前
9秒前
阳光莲小蓬完成签到,获得积分10
9秒前
9秒前
朝暮应助WeiBao采纳,获得10
10秒前
CuSO4完成签到,获得积分10
10秒前
开心发布了新的文献求助10
10秒前
咕咕鸽完成签到,获得积分10
10秒前
Jasper应助直率的颜演采纳,获得10
10秒前
11秒前
在水一方应助善良的天德采纳,获得10
11秒前
12秒前
12秒前
12秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974943
求助须知:如何正确求助?哪些是违规求助? 3519467
关于积分的说明 11198482
捐赠科研通 3255728
什么是DOI,文献DOI怎么找? 1797904
邀请新用户注册赠送积分活动 877261
科研通“疑难数据库(出版商)”最低求助积分说明 806224